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Abstract
Inflammasomes are multi-protein complexes integrating pathogen-triggered signaling leading to 
the generation of pro-inflammatory cytokines, including interleukin-18 (IL-18). Hepatitis C virus 
(HCV) and human immunodeficiency virus-1 (HIV) infections are associated with elevated IL-18, 
suggesting inflammasome activation. However, there is marked person-to-person variation in the 
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inflammasome response to HCV and HIV. We hypothesized that host genetics may explain this 
variation. To test this, we analyzed the associations of plasma IL-18 levels and polymorphisms in 
10 genes in the inflammasome cascade. 1538 participants with active HIV and/or HCV infection 
in 3 ancestry groups are included. Samples were genotyped using the Illumina Omni 1-quad and 
Omni 2.5 arrays. Linear regression analyses were performed to test the association of variants with 
logIL-18 including HCV and HIV infection status and HIV-RNA, in each ancestry group and then 
meta-analyzed. Eleven highly correlated SNPs (r2=0.98-1) in the IL18-BCO2 region were 
significantly associated with logIL-18; Each T allele of rs80011693 confers a decrease of 0.06 log 
pg/mL of IL-18 after adjusting for covariates (rs80011693; rs111311302 β=-0.06, P-
value=2.7×10-4). In conclusion, genetic variation in IL18 is associated with IL-18 production in 
response to HIV and HCV infection and may explain variability in the inflammatory outcomes of 
chronic viral infections.
Introduction
Inflammasomes are multi-protein cytosolic complexes that integrate several pathogen-
triggered signaling cascades, ultimately leading to caspase-1 activation and the generation of 
pro-inflammatory cytokines including interleukin (IL)-18 and IL-1β (1,2). While there are 
inflammasome-dependent and -independent means to induce mature IL-1β production (3-5), 
to date, inflammasome activation has been the only mechanism described to convert pro-
IL-18 to mature IL-18 (6). Thus, higher levels of IL-18 are indicative of inflammasome 
activation. Both hepatitis C virus (HCV) and human immunodeficiency virus-1 (HIV) are 
known to activate a specific inflammasome, the NOD-like receptor (NLR) family, pyrin 
domain containing 3 (NLRP3) inflammasome, as measured by increases in IL-18. For 
example, plasma IL-18 levels increase sharply during the acute phase of HCV infection, 
remain elevated in those with persistent infection, and return to the pre-infection level with 
spontaneous resolution of HCV (7). Similarly, levels are elevated in patients with chronic 
hepatitis and cirrhosis, and reduced after the infection is resolved either spontaneously (8) or 
after antiviral treatment (9). IL-18 levels are also elevated in HIV infection, an effect that is 
partially reversed by antiretroviral therapy (10,11).
Genetic determinants of IL-18 levels have been demonstrated in cohorts of individuals from 
different age groups without chronic viral infections (12-14). Several independent loci have 
been correlated with serum IL-18 levels in multiple genome-wide association studies 
including the interleukin 18 and beta-carotene oxygenase 2 (IL18-BCO2) gene region of 
chromosome 11 and, the NLR family, and caspase activation and recruitment domains 
(CARD) domain containing 4 (NLRC4) gene on chromosome 2 (12-14). Associations of 
serum IL-18 levels and SNPs in the IL18 gene were replicated in several populations of 
European ancestry with different demographic characteristics including women with no 
history of chronic illness (14), women with and without Type 2 diabetes (14), individuals 
with and without premature coronary heart disease (15) and older adults (12). Strong genetic 
effects in cis location have been suggested, however the biological mechanisms underlying 
the genetic associations are unknown.
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Compared to what is observed in studies of persons without chronic viral infection, there is a 
wider range of IL-18 elevation observed in persons with chronic viral infection that cannot 
be explained by age, race, or gender (2,7,16,17). This suggests that host genetic differences 
may partially explain variation in IL-18 response to viral infection. To investigate this 
hypothesis, we measured IL-18 levels in individuals with well-characterized chronic and 
active HIV viremia and/or HCV viremia and evaluated the association of single nucleotide 
polymorphisms (SNPs) in 10 key genes in the viral-NLPR3 inflammasome activation 
pathway.
Results
Participants
Demographic characteristics of the analyzed individuals are presented in Table 1. HIV 
infected individuals were not under antiretroviral therapy. All individuals had their ancestry 
defined by principal component analysis using genetic variants. There were 386 individuals 
of European Ancestry (EA), 796 of African Ancestry (AA) and 356 of mixed or other 
Ancestry (MOA). Age (P value= 0.94), ancestry (P value = 0.09) and sex (P value= 0.13) 
were not associated with log IL-18.
Log plasma IL-18 by infection status
Log IL-18 was significantly higher in 450 persons with both HIV and HCV infections 
(Mean =2.76 log pg/mL, SD=0.27 log pg/mL) than in the 668 HIV-mono infected 
(Mean=2.61 log pg/mL, SD=0.30 log pg/mL) and the 420 HCV mono infected participants 
(Mean=2.50 log pg/mL, SD=0.30 log pg/mL), P = 2.2 × 10-16 for the three-group 
comparison, Figure 1. Similar results were observed for each ancestry group independently 
(Supplementary Figure 1). The multivariable analysis after adjusting for the principal 
components demonstrates that the level of HIV RNA in plasma is also determinant of IL-18 
levels in all individuals (Table 2) as well as in each ancestry group (Supplementary Table 1). 
Specifically, there was a progressive increase in log IL-18 as HIV RNA increases from low, 
to moderate and high levels in both the HIV monoinfected and HIV-HCV co-infected groups 
compared to the HCV monoinfected individuals. However, HIV/HCV infection, HIV RNA 
and principal components, only accounted for 14% of the variance in IL-18 levels.
Genetic association analysis
From 10 genes spanning a total of ∼519 kb of DNA (Supplementary Table 2), we evaluated 
721 genetic variants for EA, 1307 for AA, and 1170 for MOA. We found an association of 
IL-18 levels and variants in the IL18-BCO2 region in chromosome 11. The SNPs 
significantly associated with IL-18 levels after adjusting for the principal components and 
the HIV and HCV categories are shown in Figure 2. Table 3 displays their allelic frequency, 
effect size estimates and the annotation of the function and eQTL information described in 
public databases (https://genome.ucsc.edu/index.html and http://www.gtexportal.org/home/, 
respectively). The strongest signals in the IL18-BCO2 region were in the imputed SNPs 
rs80011693 (β=-0.06, SE=0.02, P value=1.9 × 10-4) and rs111311302 with β=-0.06, 
SE=0.02, P value=2.0 × 10-4. Thus, each T allele of rs80011693 confers a decrease of 0.06 
log pg/mL of IL-18 after adjusting for HIV-HCV infection, HIV RNA levels and ancestry 
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(Table 3 and Supplementary Table 3). The direction of the effect of the associated variants is 
the same across ancestry groups. They were in high linkage disequilibrium (LD) in the three 
ancestry groups (r2=0.98-1). After conditioning on each of the associated SNPs, the 
remaining SNPs in the IL18-BCO2 were not significant (Supplementary Figure 3), 
highlighting the strong LD across this region. Associations between log IL-18 and 
polymorphisms in IL-1β, ASCC1, NLRP3, NFKB1, NFKB2, CASP1, TLR7, TLR8 and 
MYD88 did not reach statistical significance after correcting for multiple tests.
Discussion
This investigation extends previous associations of genetic factors with IL-18 plasma levels 
by demonstrating that the variants in the IL18-BCO2 region are important determinants of 
plasma IL-18 levels in the presence of a chronic viral infection. Prior studies demonstrated 
the importance of this region in persons without an ongoing infection (12-14). Compared to 
the SNPs, the greater magnitude of the effects (β regression coefficient) associated with HIV 
mono infection and HIV-HCV co-infection confirm the dominant role of viral infections 
explaining person to person differences in IL-18 levels (7, 8). However, these dominant viral 
associations only accounted for a low percentage of the variance in IL-18 levels, suggesting 
that there are other unmeasured factors responsible for the person-to-person differences in 
IL-18 levels in each infection group. Our findings suggest that this genetic region has an 
important role in determining plasma IL-18 levels. It is also notable that in our multivariable 
model, no other non-genetic factor was as important, including ancestry.
The results of this and previous studies indicate a consistent locus effect in the IL18 region 
represented by a SNP to SNP replication across studies. The association of genetic variants 
in IL18 on plasma IL-18 levels was studied in older European adults included in the 
Cardiovascular Health Study (CHS) (12) and European individuals in the In-CHIANTI study 
(13). They detected an association of IL-18 levels with rs1834481 and rs5744256, two 
intronic SNPs that were also significantly associated with IL-18 levels in our study. 
Likewise, rs1834481 was associated with IL-18 levels in a genome wide association study of 
1,523 women of European ancestry from the Nurses' Health Study (NHS) and 435 from the 
Women's Genome Health Study (WGHS) (14). Moreover, rs5744256 and rs2043055 were 
previously associated with IL-18 levels in candidate gene studies in healthy individuals and 
in individuals with premature cardiovascular disease, respectively (15,18,19).
We looked at the publicly available RNA expression data (20,21) to investigate the 
relationship of any of the associated SNPs or other SNPs with expression of IL-18 levels in 
diverse tissues. Of the 11 variants described in this study, 10 have been described as 
expression quantitative trait loci (eQTLs) in tissues such as lung, pancreas and skin (21). 
Other SNPs not included in the present analysis, such as rs7020926, rs7030024, 
rs13283237,rs7851038 and rs944363, are described as related to IL-18 expression levels in 
circulating monocytes analyzed in 1,490 unrelated European individuals (22), but no direct 
biological mechanism has yet been demonstrated.
BCO2 variants have also been reported as associated with serum IL-18 level. In the CHS and 
In-CHIANTI cohorts, rs2250417 was significantly associated with IL-18 protein levels (13) 
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in each individual cohort as well as the meta-analysis (P value=1.9 × 10-32). Similarly, He et 
al describes three different variants (rs2115763, rs12420140, and rs4935984) in this gene as 
associated with IL-18 levels in the NHS-WGHS (14). The associated variants in the BCO2 
gene in the different studies (rs2250417, rs10891343, rs2115763, rs12420140, and 
rs4935984) are in high LD (D′=0.99-1) with the associated SNPs in our study in populations 
of African, European, Asian descent as well as admixed populations in The 1000 Genomes 
project (http://www.1000genomes.org/). However, since they were not genotyped or imputed 
in this study, we cannot rule out their role on IL-18 levels in this analysis.
Even though there is a clear effect of genetic determinants in plasma IL-18 levels, much of 
the inter-individual differences remain unexplained. Circulating levels and biological activity 
depends on the level of production of IL-18, its natural inhibitory protein IL-18BP (IL-18 
binding protein) as well as the surface expression of IL-18 receptors (IL-18R) on responding 
cells (23). Thus, variation in the levels of IL-18 might be determined by polymorphisms 
regulating the expression of these genes or as yet unidentified genes that encode for the 
proteins that interact with IL-18. Environmental factors such as bacterial and other viral 
infections stimulating the innate and acquired immune responses concurrently with HCV 
and HIV may also affect IL-18 levels. However, IL-18 levels have been shown to be stable 
both before (low levels) and in the chronic phase of (high levels) HCV infection, suggesting 
that exposure to other infections may play a lesser role than HCV in regulating total levels. 
Additionally, chronic or acute conditions activating the inflammasome, and epigenetic 
mechanisms regulating the expression of the IL-18 protein are among other potential 
modulators of IL-18 variation.
On the other hand, pro-IL-18 is constitutively expressed (24,25), its expression increases 
from baseline levels after the signal 1 and inflammasome assembly results in maturation of 
IL-18, and its release into extracellular space (26,27). We hypothesize that baseline 
constitutive expression levels of pro-IL-18 are regulated by genetic determinants represented 
by the associated variants and, that caspase 1 activation converts pro-IL-18 to mature IL-18 
with greater production of mature IL-18 when pro-IL-18 levels are higher. Thus, the higher 
baseline pro-IL-18 in the individuals with the risk alleles result in higher levels of mature 
IL-18 production upon inflammasome activation. This would be expected if caspase 1 
enzymatic activity is not limiting upon activation and is consistent with the literature on 
IL-18 regulation (24,28). Our perspective is also influenced by the observation we make in 
humans infected with HIV or HCV in whom there is a marked increase in plasma total IL-18 
that remains elevated for decades or until with HCV, the infection is eliminated, at which 
time it comes back to baseline (7). Those increases in total plasma IL-18 level following 
HCV or HIV infection vary markedly from person to person, persist for decades, and 
undoubtedly are multifactorial but yet poorly understood. Thus, we aimed to study the full 
range of genes that might contribute, even if the gene doesn't fit the current models of 
inflammasome activation. We established that there is a genetic basis for differences in 
plasma IL-18 levels in persons with chronic viral infection that warrants investigation of the 
molecular mechanisms underlying those observations.
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Materials and Methods
Study participants
A total of 1538 individuals were selected from 5 different study cohorts: the AIDS Link to 
the Intravenous Experience (ALIVE) (29), Baltimore Before and After Acute Study of 
Hepatitis (BBAASH) (30), Boston Area HCV Study Transmission, Immunity, Outcomes 
Network (BAHSTION) (31), Correlates of Resolved Versus Low-Level Viremic Hepatitis C 
Infection in Blood Donors (REVELL Study) (32), and Women's Interagency HIV Study 
(WIHS) (33), as previously described (34). The inclusion criteria were the availability of 
genome-wide genotyping data and evidence of active HCV and/or HIV infection as 
determined by presence of both antibodies and detectable RNA levels for more than 6 
months prior to the date of IL-18 testing, as described previously (33,34). HCV and/or HIV 
infected individuals were not included in any anti-HCV or antiretroviral therapy at the time 
of sample withdraw. Each individual study obtained consent for genetic testing as approved 
by their governing Institutional Review Board and the Johns Hopkins School of Medicine 
Institutional Review Board.
IL-18 plasma levels
Mature IL-18 was measured in plasma from reposited specimens using enzyme-linked 
immunosorbent assay (MBL International, Woburn, MA, USA) on a sample taken prior to 
antiretroviral therapy in the HIV-infected participants. The assay was performed per the 
manufacturer's recommendations using 50 μL of plasma. Data were acquired using a 
SpectraMax M5 (Molecular Devices). The sensitivity of this assay is 12.5 pg/mL and the 
average intra-assay coefficient of variation is 7.25%.
Statistical analysis
Plasma IL-18 levels, log-transformed for approximate normalization, were the primary 
outcome. HIV and HCV infection status, HIV RNA levels, genetic ancestry, gender, and age 
were each included in the statistical model of linear regression to determine their effect on 
logIL-18. HCV and HIV infection status and HIV RNA variables were modeled as a unique 
categorical variable that we refer to as “HIV-HCV infection, HIV RNA”. This variable 
groups the individuals into seven categories: HCV mono infected, HIV mono infected with 
low (400-10K copies/mL), moderate (10K-50K copies/mL) and high HIV RNA levels 
(>50K copies/mL) and, co-infected with low, moderate and high HIV RNA levels. ANOVA 
was used to compare log IL-18 levels between HCV mono infected, HIV mono infected, and 
HIV-HCV co-infected individuals with all individuals and by genetic ancestry.
Genetic ancestry analysis
Genetic ancestry was determined by principal components based on 10,340 unlinked SNPs 
across the genome using the smartpca program from the software package eigenstrat (35). 
Principal components analysis is used to summarize the background genetic variation of 
populations into a few variables that represent ancestral origin. Three distinct ancestry 
groups emerged including European Ancestry, African Ancestry and mixed or other 
ancestry, which likely includes Hispanic and Asian ancestry (Supplementary Figure 2).
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Genotyping and Imputation
The SNP genotyping data were obtained from a larger genome wide association study (34) 
using the Illumina Human Omni-Quad array for samples from the ALIVE, BBAASH, 
BAHSTION and REVELL study groups and using the Illumina Omni2.5 array for the WIHS 
group. The selected SNPs are part of the NLRP3 inflammasome pathway and include the 
genes and 10 kilobases upstream and downstream of each gene. The pathway genes included 
were Interleukin 18 (IL18), Interleukin 1 beta (IL-1β), Activating Signal Cointegrator 1 
Complex Subunit 1 (ASCC1), NLR family, pyrin domain containing 3 (NLRP3); Nuclear 
Factor Kappa B Subunit 1 (NF-κβ1), Nuclear Factor Kappa B Subunit 2 (NF-κβ2), Caspase 
(CASP1), Toll Like Receptor 7 (TLR7), Toll Like Receptor 8 (TLR8), Myeloid 
Differentiation Primary Response 88 (MYD88) and Beta-carotene oxygenase 2 (BCO2). 
Genomic coordinates were based on the Human GRCh37/hg19 assembly (Supplementary 
Table 2). Genomic imputation was performed for each chromosomal region using IMPUTE2 
(36). The reference panel consisted of 2,504 individuals representing four continental 
populations (Africa, Americas, Asia and Europe) as part of the 1000 Genomes Project (37). 
Each genetic platform was individually imputed using all individuals and the imputed 
datasets were merged based on genetic ancestry groups using the software Plink version 1.90 
beta (https://www.cog-genomics.org/plink2). Only variants with an information score > 0.3 
and a genotyping probability greater than 90% were included in the analysis (38). Standard 
quality control measures were employed pre and post imputation (excluding variants with 
minor allele frequency (MAF) < 0.01, missing call rate ≥ 1%, Hardy Weinberg equilibrium 
test P value < 1×10−5). Genotyped and high quality imputed variants that were common to 
both platforms were included in the regression analysis.
Genetic association analysis
Plink was used to analyze linear regression models adjusting for five principal components 
and HIV-HCV infection, HIV RNA. SNPs were modeled under an additive model in which 
genotypes are represented as 0, 1, 2 copies of the minor allele. Ancestry groups were tested 
separately and the results were meta-analyzed by combining ancestry-specific β (regression 
coefficient) estimates using a fixed effects inverse variance model (39) implemented in 
META (40). Linkage disequilibrium (r2) was determined in each of the genetic regions by 
ancestral group. This informed a modified Bonferroni correction using the effective number 
of independent SNPs (n=103 SNPs for AA, n=38 for EA and n=57 for MOA, n= 197 total 
variants). Twenty-five of the 197 SNPs were common between at least two ancestry groups, 
and the remaining were unique. A modified Bonferroni corrected P value < 2.9 × 10-4 was 
considered statistically significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Log plasma IL-18 by HCV and HIV infection status in all the individuals analyzed in the 
study. The thick horizontal line in each box plot represent the median for each category, the 
whiskers extend to 1.5 times the interquartile range from the box.
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Figure 2. 
Association of variants in the IL18-BCO2 region. The variants included 14 genotyped 
(squares) and 177 imputed SNPs (circles) within the region from 112 Mb to 112.1 Mb on 
chromosome 11. The recombination in this region is plotted in the background in light blue. 
Pair wise LDs between rs80011693 and other variants in IL18-BCO2 were estimated using 
LD data in EUR population in the 1000 Genomes project (hg19/Nov 2014). The color from 
blue to red represents the r2 values.
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Table 1
Descriptive statistics of the analyzed individuals by genetically estimated ancestry group.
Characteristic
Genetically estimated Ancestry groups
European (n=386) African (n=796) Mixed or other (n=356)
Female (n, %) 283 (73.3) 703 (88.3) 334 (93.8)
Age (years), mean (SD) 41.37 (11.5) 40.85 (8.5) 37.51 (9.4)
IL-18 (pg/mL), mean (SD) 584.5 (547.4) 546.0 (441.3) 560.3 (410.0)
HIV HCV infection status and HIV RNA
HCV Mono infected (n, %) 191 (49.5) 156 (19.6) 73 (20.5)
HIV Mono infected, low HIV RNA1(n, %) 28 (7.25) 104 (13.1) 58 (16.29)
HIV Mono infected, moderate HIV RNA1 (n, %) 35 (9.06) 102 (12.8) 62 (17.4)
HIV Mono infected, high HIV RNA1 (n, %) 56 (14.5) 149 (18.7) 74 (20.78)
HIV HCV Co-infected, low HIV RNA (n, %) 19 (4.92) 75 (9.42) 35 (9.83)
HIV HCV Co-infected, moderate HIV RNA (n, %) 21 (5.44) 76 (9.54) 20 (5.61)
HIV HCV Co-infected, high HIV RNA (n, %) 36 (9.32) 134 (16.8) 34 (9.55)
1
HIV low, medium and high RNA refers to 400-10K, 10K-50K and >50K HIV copies/mL, respectively.
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Table 2
Multivariate linear regression analysis of Log IL-18 in all individuals.
Factor β SE P value
PC1 0.12 0.16 0.46
PC2 0.24 0.16 0.13
PC3 -0.01 0.16 0.94
PC4 0.19 0.16 0.25
PC5 -0.12 0.16 0.43
HIV Mono infected, low HIV RNA 1 -0.05 0.02 0.03
HIV Mono infected, moderate HIV RNA 1 0.02 0.02 0.28
HIV Mono infected, high HIV RNA 1 0.19 0.02 2×10-16
HIV HCV Co-infected, low HIV RNA 0.15 0.02 7.0×10-08
HIV HCV Co-infected, moderate HIV RNA 0.18 0.02 4.2×10-10
HIV HCV Co-infected, high HIV RNA 0.27 0.02 2×10-16
Abbreviations: β: Beta regression coefficient; SE: Standard error; PC: principal component.
1
HIV low, medium and high RNA refers 400-10K, 10K-50K and >50K HIV copies/mL, respectively.
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